Compare Amgen, Inc. (AMGN) vs Chewy Inc (CHWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Chewy Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Chewy Inc trades at $20.89 (market cap $8.55B). The key difference: Amgen, Inc. is far larger — about 22.9× Chewy Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| AMGN | CHWY | |
|---|---|---|
Market Cap | $196.12B | $8.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $42.33 |
52-Week Low | $271.18 | $17.51 |
Enterprise Value | $241.41B | $8.51B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Chewy (CHWY) trades at $20.88, up 1.02% today, but remains under pressure with a bearish technical signal and recent earnings misses. The company reported strong revenue growth to $11.86B in 2025 and improved net income of $393M, yet faces margin compression and lowered FY26 sales guidance. Analyst sentiment remains overwhelmingly positive with 81.58% buy ratings and a $34.92 consensus target, suggesting significant upside potential from current levels despite near-term challenges.
The investment case balances attractive valuation metrics (P/S 0.69) against cyclical headwinds and competitive pressures. While operational cash flow growth and market share gains in pet healthcare provide long-term catalysts, investor caution is warranted given recent guidance reductions and volatile technical positioning near key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
